News

Embody Announces $20.5M Funding Round

Embody, Inc., a privately-held medical device company focused on soft tissue healing, announced that it has secured $11.5 million in an oversubscribed equity financing and entered into a debt financing agreement led by Horizon Technology Finance Corporation to provide up to $9 million in term loans, of which an initial $5 million has been funded, for a total of $20.5 million in available funds.  The funding will support the support the commercialization of Tapestry Biointegrative Implant, the launch of the Tapestry RCR system and post-market clinical studies of the Tapestry platform.

“We are pleased to have the support of our existing and new investors and to partner with Horizon, a leading venture debt provider that has an extensive history of supporting innovative life science companies,” said Jeff Conroy, Chief Executive Officer of Embody. “Through the second half of 2021 and early 2022, we anticipate a number of important milestones in the commercial expansion of our Tapestry platform.  This transaction immediately strengthens and extends our financial resources to advance our position in the market with the launch of Tapestry RCR for arthroscopic rotator cuff and our clinical pipeline.”

“We are delighted to provide this financing to Embody and have confidence in the Company’s technology and business strategy,” said Gerald A. Michaud, President of Horizon.  “We look forward to the Company reaching its critical milestones for its novel collagen technology platforms for soft tissue healing in sports medicine where there is a scarcity of technologies addressing the unmet needs of shoulder, knee, and foot & ankle injuries.”

Recent News

05/14/2025

Civica to start Chesterfield lab construction this summer, eyes Petersburg plant expansion

Nearly three years after announcing plans to build a laboratory in Chesterfield to support its manufacturing operations in Petersburg, Civica Rx is readying plans to kick off the project’s construction. The Utah-based nonprofit drugmaker said it will break ground this summer on a 50,000-square-foot facility at 11731 Meadowville Lane, in the Meadowville Technology Park near Chester.

05/07/2025

Adial Pharmaceuticals raises $2.75M

Glen Allen biopharma company Adial Pharmaceuticals Inc. (NASDAQ: ADIL) has raised $2.75 million from an institutional investor. The company, which specializes in therapies for addiction and related disorders, said it will use the new funding for working capital and general corporate purposes. The name of the investor was not disclosed, but Adial said a “health

05/07/2025

Adovate Granted New U.S. Patent for Therapeutic Uses of A2B Receptor Antagonists

Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company developing novel therapeutics targeting adenosine receptors involved in major diseases, today announced that Patent Number 12,269,828 B2 was issued by the United States Patent and Trademark Office. This newly issued patent covers therapeutic uses of the Company’s lead molecule ADO-5030 and thousands of other novel molecules